Fig. 1From: Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patientsThe cost-effectiveness plane for apixaban versus warfarin. Green line depicts ICER threshold equal to the Finnish GDP and red line depicts ICER threshold equal to 3 times the Finnish GDP Back to article page